Key Takeaways
- • Arizona's bioscience sector achieved record venture capital funding of nearly $200 million in 2019, alongside $263 million in National Institutes of Health grants to universities, research institutes, and firms—the highest levels since Arizona's Bioscience Roadmap tracking began nearly 20 years ago.
- • University research and development spending surged 25% between 2016 and 2018, exceeding $600 million, reflecting sustained institutional investment in the state's bioscience ecosystem.
- • The sector generated nearly 10,000 new bioscience jobs over a two-year span (2016–2018) with wage growth of approximately 9%, substantially outpacing Arizona's average private-sector wage growth.
- • Arizona's bioscience workforce expansion and wage gains significantly exceeded state and national employment trends, positioning the sector as a critical economic driver and demonstrating the effectiveness of the Bioscience Roadmap strategy through 2025.
- • The strengthened bioscience infrastructure and research capacity positioned Arizona institutions and companies to contribute meaningfully to pandemic response efforts, particularly in COVID-19 tracking and treatment initiatives.
Summary
Arizona's bioscience sector has reached historic performance levels across all major metrics tracked since the launch of the state's Bioscience Roadmap nearly two decades ago, according to an April 15 performance analysis commissioned by the Phoenix-based Flinn Foundation. The sector's momentum reflects sustained policy support and strategic investment that has transformed Arizona into an emerging bioscience hub with measurable economic impact.
Venture capital funding for Arizona bioscience firms totaled nearly $200 million in 2019, marking a record high for the state. Complementing private investment, federal research funding proved equally robust: National Institutes of Health grants to Arizona universities, research institutes, and companies reached $263 million in 2019. Perhaps most significantly, university research and development spending increased 25% between 2016 and 2018, climbing to exceed $600 million across the period. All three funding categories represent peak levels in Arizona's tracked bioscience history.
Employment and wage growth in the sector substantially outpaced broader economic trends. Arizona added 9,696 bioscience industry jobs between 2016 and 2018, with wage growth climbing approximately 9%—far exceeding the state's average private-sector wage gains. This employment expansion demonstrates that Arizona's bioscience investment strategy has translated into tangible workforce development and wage premium benefits for workers in the sector.
Flinn Foundation President and CEO Tammy McLeod emphasized the strategic significance of the sector's growth, noting that "the state's sustained dedication to the goals and strategies of the Bioscience Roadmap has created a bioscience community prepared to play an instrumental role in the tracking and treatment of COVID-19 and assist in the state's economic recovery." The observation underscores how multi-year infrastructure development in research funding, university partnerships, and venture capital access creates institutional readiness for emerging crises and economic challenges.
The April 2020 report signals that Arizona's policy framework supporting bioscience development—anchored by the Bioscience Roadmap through 2025—has successfully built a diversified funding ecosystem combining venture capital, federal research grants, and university R&D investment, creating a competitive advantage for the state's research institutions and bioscience firms during periods of economic uncertainty.
Venture capital funding for Arizona bioscience firms totaled nearly $200 million in 2019, marking a record high for the state. Complementing private investment, federal research funding proved equally robust: National Institutes of Health grants to Arizona universities, research institutes, and companies reached $263 million in 2019. Perhaps most significantly, university research and development spending increased 25% between 2016 and 2018, climbing to exceed $600 million across the period. All three funding categories represent peak levels in Arizona's tracked bioscience history.
Employment and wage growth in the sector substantially outpaced broader economic trends. Arizona added 9,696 bioscience industry jobs between 2016 and 2018, with wage growth climbing approximately 9%—far exceeding the state's average private-sector wage gains. This employment expansion demonstrates that Arizona's bioscience investment strategy has translated into tangible workforce development and wage premium benefits for workers in the sector.
Flinn Foundation President and CEO Tammy McLeod emphasized the strategic significance of the sector's growth, noting that "the state's sustained dedication to the goals and strategies of the Bioscience Roadmap has created a bioscience community prepared to play an instrumental role in the tracking and treatment of COVID-19 and assist in the state's economic recovery." The observation underscores how multi-year infrastructure development in research funding, university partnerships, and venture capital access creates institutional readiness for emerging crises and economic challenges.
The April 2020 report signals that Arizona's policy framework supporting bioscience development—anchored by the Bioscience Roadmap through 2025—has successfully built a diversified funding ecosystem combining venture capital, federal research grants, and university R&D investment, creating a competitive advantage for the state's research institutions and bioscience firms during periods of economic uncertainty.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.